Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in nuclear medicine diagnosis and treatment of differentiated thyroid cancer

Yihan ZHAO; Yansong LIN

doi:10.19401/j.cnki.1007-3639.2025.09.001

您当前的位置：

首页 >

文章列表页 >

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in nuclear medicine diagnosis and treatment of differentiated thyroid cancer

Specialist's Commentary | 更新时间：2025-12-31

- Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in nuclear medicine diagnosis and treatment of differentiated thyroid cancer
- China Oncology Vol. 35, Issue 9, Pages: 815-825(2025)
- 作者机构：
  
  中国医学科学院北京协和医学院北京协和医院核医学科，疑难重症及罕见病国家重点实验室，核医学分子靶向诊疗北京市重点实验室，北京 100730
- 作者简介：
- 基金信息：
  
  National Natural Science Foundation of China(82472027)
- DOI：10.19401/j.cnki.1007-3639.2025.09.001
  CLC： R736.1
- Received：11 September 2025，
  
  Revised：2025-09-25，
  
  Published：30 September 2025
- 稿件说明：
移动端阅览
Yihan ZHAO, Yansong LIN. Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in nuclear medicine diagnosis and treatment of differentiated thyroid cancer[J]. China Oncology, 2025, 35(9): 815-825.
DOI：

Yihan ZHAO, Yansong LIN. Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in nuclear medicine diagnosis and treatment of differentiated thyroid cancer[J]. China Oncology, 2025, 35(9): 815-825. DOI： 10.19401/j.cnki.1007-3639.2025.09.001.

摘要

2025年美国甲状腺学会（American Thyroid Association，ATA）发布的《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》在分化型甲状腺癌（differentiated thyroid cancer，DTC）术后核医学诊疗方面进行了多项重要更新。本文以2025版ATA指南提出的DATA临床管理框架[DATA即诊断（Diagnosis）、风险-获益评估（risk/benefit Assessment）、治疗决策（Treatment decisions）及治疗反应评估（response Assessment）

]

为主线，系统梳理DTC术后评估、放射性碘治疗（radioactive iodine therapy，RAIT）决策、治疗反应动态评估及随访策略等方面的核医学研究进展。基于2015版ATA指南及近期研究证据，2025版ATA指南强调术后疗效评估（包括血清学和影像学评估）对实时修正风险分层的关键意义，并将复发风险由原有的低、中、高危三类细化为低、中-低、中-高和高危四类，以更精准地预测结构性复发风险；在RAIT策略方面，明确低危患者不再常规推荐清甲治疗，以减少不必要的辐射暴露，并指出重组人促甲状腺激素（recombinant human thyroid stimulating hormone，rhTSH）在低、中危患者RAIT前准备中的优先地位。本指南针对诊断性放射性碘全身显像（diagnostic whole body scan，DxWBS）、

F-FDG正电子发射计算机体层成像（positron emission tomography and computed tomography，PET/CT）等核医学分子影像学方法在临床实践中的适用场景予以进一步明确；同时，围绕RAIT后的随访策略、重复RAIT的适应证以及放射性碘难治性DTC（radioactive iodine-refractory DTC，RAIR-DTC）的判定标准与管理原则，本文提炼了2025版ATA指南中相关更新要点。

Abstract

The “2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer” released by the American Thyroid Association (ATA) in 2025 include several important updates regarding nuclear medicine diagnosis and treatment for post-operative differentiated thyroid cancer (DTC). This article systematically reviewed advances in the nuclear medicine aspects of post-operative DTC assessment

decision-making for radioactive iodine therapy (RAIT)

dynamic response evaluation

and follow-up strategies

guided by the 2025 ATA guidelines’ DATA clinical management framework—Diagnosis

risk/benefit Assessment

Treatment decisions

and response Assessment. Building on the 2015 ATA guidelines and recent research evidence

the 2025 ATA guidelines emphasize the critical importance of post-operat

ive response assessment (including serological and imaging evaluations) for the real-time refinement of risk stratification. It further subcategorizes recurrence risk from the original three categories (low

intermediate

high) to four categories (low

low-intermediate

intermediate-high and high) to more accurately predict the risk of structural recurrence. Regarding RAIT strategy

the 2025 ATA guidelines clearly state that remnant ablation is no longer routinely recommended for low-risk patients to avoid unnecessary radiation exposure

and highlight the preferred use of recombinant human thyroid stimulating hormone (rhTSH) for RAIT preparation in low- and intermediate-risk patients. The 2025 ATA guidelines further clarify the appropriate clinical application scenarios for nuclear medicine molecular imaging methods such as diagnostic whole-body scan (DxWBS) and

F-FDG positron emission tomography and computed tomography (PET/CT). At the same time

concerning post-RAIT follow-up strategies

indications for repeated RAIT

as well as the diagnostic criteria and management principles for radioactive iodine-refractory DTC (RAIR-DTC)

this article highlighted the key updated points in the 2025 ATA guideline.

关键词

Keywords

references

SINGER P A , COOPER D S , DANIELS G H , et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association [J ] . Arch Intern Med , 1996 , 156 ( 19 ): 2165 - 2172 .

RINGEL M D , SOSA J A , BALOCH Z , et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer [J ] . Thyroid , 2025 , 35 ( 8 ): 841 - 985 .

HAUGEN B R , ALEXANDER E K , BIBLE K C , et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer [J ] . Thyroid , 2016 , 26 ( 1 ): 1 - 133 . DOI: 10.1089/thy.2015.0020 http://doi.org/10.1089/thy.2015.0020

OZKAN E , SOYDAL C , NAK D , et al. Dynamic risk stratification for predicting the recurrence in differentiated thyroid cancer [J ] . Nucl Med Commun , 2017 , 38 ( 12 ): 1055 - 1059 . DOI: 10.1097/MNM.0000000000000766 http://doi.org/10.1097/MNM.0000000000000766

LEE Y M , CHO J W , HONG S J , et al. Dynamic risk stratification in papillary thyroid carcinoma measuring 1 to 4 cm [J ] . J Surg Oncol , 2018 , 118 ( 4 ): 636 - 643 .

CANO-PALOMARES A , CASTELLS I , CAPEL I , et al. Response to initial therapy of differentiated thyroid cancer predicts the long-term outcome better than classical risk stratification systems [J ] . Int J Endocrinol , 2014 , 2014 : 591285 .

MANZARDO O A , CELLINI M , INDIRLI R , et al. TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence [J ] . Endocr Relat Cancer , 2020 , 27 ( 6 ): 325 - 336 .

COOPER D S , DOHERTY G M , HAUGEN B R , et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer [J ] . Thyroid , 2009 , 19 ( 11 ): 1167 - 1214 . DOI: 10.1089/thy.2009.0110 http://doi.org/10.1089/thy.2009.0110

YWATA DE CARVALHO A , KOHLER H F , GOMES C C , et al. Predictive factors for recurrence of papillary thyroid carcinoma: analysis of 4 085 patients [J ] . Acta Otorhinolaryngol Ital , 2021 , 41 ( 3 ): 236 - 242 .

VAN VELSEN E F S , STEGENGA M T , VAN KEMENADE F J , et al. Evaluating the 2015 American Thyroid Association risk stratification system in high-risk papillary and follicular thyroid cancer patients [J ] . Thyroid , 2019 , 29 ( 8 ): 1073 - 1079 . DOI: 10.1089/thy.2019.0053 http://doi.org/10.1089/thy.2019.0053

LEE J , LEE S G , KIM K , et al. Clinical value of lymph node ratio integration with the 8(th) edition of the UICC TNM classification and 2015 ATA risk stratification systems for recurrence prediction in papillary thyroid cancer [J ] . Sci Rep , 2019 , 9 ( 1 ): 13361.

TUTTLE R M , TALA H , SHAH J , et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system [J ] . Thyroid , 2010 , 20 ( 12 ): 1341 - 1349 . DOI: 10.1089/thy.2010.0178 http://doi.org/10.1089/thy.2010.0178

VAISMAN F , MOMESSO D , BULZICO D A , et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy [J ] . Clin Endocrinol , 2012 , 77 ( 1 ): 132 - 138 . DOI: 10.1111/j.1365-2265.2012.04342.x http://doi.org/10.1111/j.1365-2265.2012.04342.x

MALANDRINO P , LATINA A , MARESCALCO S , et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin [J ] . J Clin Endocrinol Metab , 2011 , 96 ( 6 ): 1703 - 1709 . DOI: 10.1210/jc.2010-2695 http://doi.org/10.1210/jc.2010-2695

SOYLUK O , BOZTEPE H , ARAL F , et al. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment [J ] . Thyroid , 2011 , 21 ( 12 ): 1301 - 1308 . DOI: 10.1089/thy.2011.0122 http://doi.org/10.1089/thy.2011.0122

TORLONTANO M , ATTARD M , CROCETTI U , et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases [J ] . J Clin Endocrinol Metab , 2004 , 89 ( 7 ): 3402 - 3407 .

BARRES B , KELLY A , KWIATKOWSKI F , et al. Stimulated thyroglobulin and thyroglobulin reduction index predict excellent response in differentiated thyroid cancers [J ] . J Clin Endocrinol Metab , 2019 , 104 ( 8 ): 3462 - 3472 . DOI: 10.1210/jc.2018-02680 http://doi.org/10.1210/jc.2018-02680

MOMESSO D P , VAISMAN F , YANG S P , et al. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine [J ] . J Clin Endocrinol Metab , 2016 , 101 ( 7 ): 2692 - 2700 . DOI: 10.1210/jc.2015-4290 http://doi.org/10.1210/jc.2015-4290

PATEL A , SHOSTROM V , TREUDE K , et al. Serum thyroglobulin: preoperative levels and factors affecting postoperative optimal timing following total thyroidectomy [J ] . Int J Endocrinol , 2019 , 2019 : 1384651 .

PORTULANO C , PARODER-BELENITSKY M , CARRASCO N . The Na + /I - symporter (NIS): mechanism and medical impact [J ] . Endocr Rev , 2014 , 35 ( 1 ): 106 - 149 .

VIEJA A D L , DOHAN O , LEVY O , et al. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology [J ] . Physiol Rev , 2000 , 80 ( 3 ): 1083 - 1105 .

MAUGUEN A , GREWAL R K , AUGENSEN F , et al. The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients [J ] . Eur J Nucl Med Mol Imaging , 2023 , 50 ( 10 ): 2971 - 2983 .

VAN NOSTRAND D , AIKEN M , ATKINS F , et al. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer [J ] . Thyroid , 2009 , 19 ( 8 ): 849 - 855 . DOI: 10.1089/thy.2008.0419 http://doi.org/10.1089/thy.2008.0419

CHEN M K , YASREBI M , SAMII J , et al. The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer [J ] . Thyroid , 2012 , 22 ( 3 ): 304 - 309 .

WONG K K , SISSON J C , KORAL K F , et al. Staging of differentiated thyroid carcinoma using diagnostic 131 I SPECT/CT [J ] . AJR Am J Roentgenol , 2010 , 195 ( 3 ): 730 - 736 .

AVRAM A M , FIG L M , FREY K A , et al. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging [J ] . J Clin Endocrinol Metab , 2013 , 98 ( 3 ): 1163 - 1171 .

AVRAM A M , ESFANDIARI N H , WONG K K . Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning [J ] . J Clin Endocrinol Metab , 2015 , 100 ( 5 ): 1895 - 1902 . DOI: 10.1210/jc.2014-4043 http://doi.org/10.1210/jc.2014-4043

SONG H , MOSCI C , AKATSU H , et al. Diagnostic 123 I whole body scan prior to ablation of thyroid remnant in patients with papillary thyroid cancer: implications for clinical management [J ] . Clin Nucl Med , 2018 , 43 ( 10 ): 705 - 709 .

KIM S , CHUNG J K , MIN H S , et al. Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma [J ] . Nucl Med Mol Imaging , 2014 , 48 ( 2 ): 91 - 97 .

ABELLEIRA E , JERKOVICH F . Dynamic risk assessment in patients with differentiated thyroid cancer [J ] . Rev Endocr Metab Disord , 2024 , 25 ( 1 ): 79 - 93 .

CHO J W , LEE Y M , LEE Y H , et al. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients [J ] . Clin Endocrinol , 2018 , 89 ( 1 ): 100 - 109 . DOI: 10.1111/cen.13721 http://doi.org/10.1111/cen.13721

PARK J H , MOON G S , NAM K T , et al. Optimal timing of initiating dynamic risk stratification during the early postoperative period in patients with differentiated thyroid carcinoma after thyroidectomy and radioactive iodine remnant ablation [J ] . Ann Surg Oncol , 2021 , 28 ( 11 ): 6580 - 6589 . DOI: 10.1245/s10434-021-09721-5 http://doi.org/10.1245/s10434-021-09721-5

PITOIA F , JERKOVICH F . Dynamic risk assessment in patients with differentiated thyroid cancer [J ] . Endocr Relat Cancer , 2019 , 26 ( 10 ): R553-R566.

SHAH S , BOUCAI L . Effect of age on response to therapy and mortality in patients with thyroid cancer at high risk of recurrence [J ] . J Clin Endocrinol Metab , 2018 , 103 ( 2 ): 689 - 697 . DOI: 10.1210/jc.2017-02255 http://doi.org/10.1210/jc.2017-02255

TIAN T , KOU Y , HUANG R , et al. Prognosis of high-risk papillary thyroid cancer patients with pre-ablation stimulated tg <1 ng/mL [J ] . Endocr Pract , 2019 , 25 ( 3 ): 220 - 225 .

LEBOULLEUX S , BOURNAUD C , CHOUGNET C N , et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer [J ] . N Engl J Med , 2022 , 386 ( 10 ): 923 - 932 .

GIOVANELLA L , DEANDREIS D , VRACHIMIS A , et al. Molecular Imaging and theragnostics of thyroid cancers [J ] . Cancers (Basel) , 2022 , 14 ( 5 ): 1272.

BARTEL T B , MAGEREFTEH S , AVRAM A M , et al. SNMMI procedure standard for scintigraphy for differentiated thyroid cancer [J ] . J Nucl Med Technol , 2020 , 48 ( 3 ): 202 - 209 . DOI: 10.2967/jnmt.120.243626 http://doi.org/10.2967/jnmt.120.243626

LI J H , HE Z H , BANSAL V , et al. Low iodine diet in differentiated thyroid cancer: a review [J ] . Clin Endocrinol , 2016 , 84 ( 1 ): 3 - 12 . DOI: 10.1111/cen.12846 http://doi.org/10.1111/cen.12846

LIM C Y , KIM J Y , YOON M J , et al. Effect of a low iodine diet vs . restricted iodine diet on postsurgical preparation for radioiodine ablation therapy in thyroid carcinoma patients [J ] . Yonsei Med J , 2015 , 56 ( 4 ): 1021 - 1027 .

SCHLUMBERGER M , LEBOULLEUX S , CATARGI B , et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial [J ] . Lancet Diabetes Endocrinol , 2018 , 6 ( 8 ): 618 - 626 .

DEHBI H M , MALLICK U , WADSLEY J , et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial [J ] . Lancet Diabetes Endocrinol , 2019 , 7 ( 1 ): 44 - 51 .

XIAO J , YUN C H , CAO J J , et al. A pre-ablative thyroid-stimulating hormone with 30-70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients [J ] . Sci Rep , 2021 , 11 ( 1 ): 1348.

VRACHIMIS A , RIEMANN B , MÄDER U , et al. Endogenous TSH levels at the time of 131 I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality [J ] . Eur J Nucl Med Mol Imaging , 2016 , 43 ( 2 ): 224 - 231 .

MATRONE A , LATROFA F , TORREGROSSA L , et al. Changing trend of thyroglobulin antibodies in patients with differentiated thyroid cancer treated with total thyroidectomy without 131 I ablation [J ] . Thyroid , 2018 , 28 ( 7 ): 871 - 879 .

BUENO F , FALCONE M G G , PEÑALOZA M A , et al. Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer [J ] . Endocrine , 2020 , 67 ( 2 ): 387 - 396 . DOI: 10.1007/s12020-019-02112-7 http://doi.org/10.1007/s12020-019-02112-7

Qichang W , Lin B , Gege Z , et al. Diagnostic performance of 18 F-FDG-PET/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis [J ] . Eur J Endocrinol , 2019 , 181 ( 2 ): 93 - 102 . DOI: 10.1530/EJE-19-0261 http://doi.org/10.1530/EJE-19-0261

ARAZ M , SOYDAL Ç , ÖZKAN E , et al. Role of thyroglobulin doubling time in differentiated thyroid cancer and its relationship with demogra phic-histopathologic risk factors and 18 F-fluorodeoxyglucose positron emission tomography/computed tomography parameters [J ] . Cancer Biother Radiopharm , 2021 , 36 ( 5 ): 425 - 432 .

ALBANO D , TULCHINSKY M , DONDI F , et al. The role of Tg kinetics in predicting 2-[ 18 F ] -FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131 I-scan [J ] . Endocrine , 2021 , 74 ( 2 ): 332 - 339 .

ALBANO D , TULCHINSKY M , DONDI F , et al. Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [ 18 F ] FDG PET/CT in non-iodine avid differentiated thyroid carcinoma [J ] . Eur J Nucl Med Mol Imaging , 2021 , 48 ( 2 ): 461 - 468 .

WANG H X , DAI H Y , LI Q R , et al. Investigating 18 F-FDG PET/CT parameters as prognostic markers for differentiated thyroid cancer: a systematic review [J ] . Front Oncol , 2021 , 11 : 648658 .

CASTAGNA M G , MAINO F , CIPRI C , et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients [J ] . Eur J Endocrinol , 2011 , 165 ( 3 ): 441 - 446 . DOI: 10.1530/EJE-11-0466 http://doi.org/10.1530/EJE-11-0466

HONG C M , LEE W K , JEONG S Y , et al. Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation [J ] . Nucl Med Commun , 2014 , 35 ( 11 ): 1119 - 1126 . DOI: 10.1097/MNM.0000000000000183 http://doi.org/10.1097/MNM.0000000000000183

KOWALSKA A , WALCZYK A , PAŁYGA I , et al. The delayed risk stratification system in the risk of differentiated thyroid cancer recurrence [J ] . PLoS One , 2016 , 11 ( 4 ): e0153242.

JEON M J , KIM M , PARK S , et al. A follow-up strategy for patients with an excellent response to initial therapy for differentiated thyroid carcinoma: less is better [J ] . Thyroid , 2018 , 28 ( 2 ): 187 - 192 . DOI: 10.1089/thy.2017.0130 http://doi.org/10.1089/thy.2017.0130

PÉREZ-FERNÁNDEZ L , SASTRE J , ZAFÓN C , et al. Validation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study [J ] . Front Endocrinol (Lausanne) , 2023 , 13 : 1071775 .

PITOIA F , JERKOVICH F , URCIUOLI C , et al. Implementing the modified 2009 American Thyroid Association risk stratification system in thyroid cancer patients with low and intermediate risk of recurrence [J ] . Thyroid , 2015 , 25 ( 11 ): 1235 - 1242 . DOI: 10.1089/thy.2015.0121 http://doi.org/10.1089/thy.2015.0121

YOON J , YOON J H , HAN K , et al. Ultrasonography surveillance in papillary thyroid carcinoma patients after total thyroidectomy according to dynamic risk stratification [J ] . Endocrine , 2020 , 69 ( 2 ): 347 - 357 . DOI: 10.1007/s12020-020-02347-9 http://doi.org/10.1007/s12020-020-02347-9

TRIMBOLI P , ZILIOLI V , IMPERIALI M , et al. High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas [J ] . Eur J Endocrinol , 2017 , 176 ( 5 ): 497 - 504 . DOI: 10.1530/EJE-16-1011 http://doi.org/10.1530/EJE-16-1011

MAZZAFERRI E L , JHIANG S M . Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer [J ] . Am J Med , 1994 , 97 ( 5 ): 418 - 428 . DOI: 10.1016/0002-9343(94)90321-2 http://doi.org/10.1016/0002-9343(94)90321-2

HIRSCH D , GORSHTEIN A , ROBENSHTOK E , et al. Second radioiodine treatment: limited benefit for differentiated thyroid cancer with locoregional persistent disease [J ] . J Clin Endocrinol Metab , 2018 , 103 ( 2 ): 469 - 476 . DOI: 10.1210/jc.2017-01790 http://doi.org/10.1210/jc.2017-01790

HUNG M L , WU J X , LI N , et al. Association of radioactive iodine administration after reoperation with outcomes among patients with recurrent or persistent papillary thyroid cancer [J ] . JAMA Surg , 2018 , 153 ( 12 ): 1098 - 1104 . DOI: 10.1001/jamasurg.2018.2659 http://doi.org/10.1001/jamasurg.2018.2659

SONG H J , QIU Z L , SHEN C T , et al. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors [J ] . Eur J Endocrinol , 2015 , 173 ( 3 ): 399 - 408 .

JANNIN A , LAMARTINA L , MOUTARDE C , et al. Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival [J ] . Eur J Nucl Med Mol Imaging , 2022 , 49 ( 7 ): 2401 - 2413 .

QIU Z L , SONG H J , XU Y H , et al. Efficacy and survival analysis of 131 I therapy for bone metastases from differentiated thyroid cancer [J ] . J Clin Endocrinol Metab , 2011 , 96 ( 10 ): 3078 - 3086 .

中国临床肿瘤学会核医学专家委员会 , 中国临床肿瘤学会甲状腺癌专家委员会 , 中华医学会核医学分会 , 等 . 放射性碘难治性分化型甲状腺癌诊治管理指南(2024版) [J ] . 中华核医学与分子影像杂志 , 2024 , 44 ( 6 ): 359 - 372 .

Nuclear Medicine Expert Committee of Chinese Society of Clinical Oncology, Thyroid Cancer Expert Committee of Chinese Society of Clinical Oncology , Chinese Society of Nuclear Medicine , et al. Management guidelines for diagnosis and treatment of refractory differentiated thyroid cancer with radioiodine (2024 edition) [J ] . Chin J Nucl Med Mol Image , 2024 , 44 ( 6 ): 359 - 372 .

LIN Y S , WANG R F , HUANG R , et al. Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition) [J ] . Eur J Nucl Med Mol Imaging , 2025 , 52 ( 10 ): 3859 - 3876 .

BROWN A P , CHEN J , HITCHCOCK Y J , et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer [J ] . J Clin Endocrinol Metab , 2008 , 93 ( 2 ): 504 - 515 .

RUBINO C , DE VATHAIRE F , DOTTORINI M E , et al. Second primary malignancies in thyroid cancer patients [J ] . Br J Cancer , 2003 , 89 ( 9 ): 1638 - 1644 .

REINECKE M J , AHLERS G , BURCHERT A , et al. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma—a critical review and evaluation of the existing evidence [J ] . Eur J Nucl Med Mol Imaging , 2022 , 49 ( 9 ): 3247 - 3256 .

PASQUAL E , SCHONFELD S , MORTON L M , et al. Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies [J ] . J Clin Oncol , 2022 , 40 ( 13 ): 1439 - 1449 . DOI: 10.1200/JCO.21.01841 http://doi.org/10.1200/JCO.21.01841

TENG C J , HU Y W , CHEN S C , et al. Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: a nationwide population-based study [J ] . J Natl Cancer Inst , 2016 , 108 ( 2 ): djv314.

Views

482

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in external beam radiotherapy (EBRT) for differentiated thyroid cancer

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in ultrasound, CT, MRI and ablation of thyroid nodules and differentiated thyroid cancer

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: precision treatment guided by genotyping

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: perioperative assessment and management of parathyroid function and precision individualized management of postoperative TSH suppression in adults with differentiated thyroid cancer

The unique value and controversy of nuclear medicine molecular imaging in the evaluation of radioiodine-refractory differentiated thyroid cancer

Related Author

Xiaorong HOU

Xiaoliang LIU

Ruyu LIU

Chenyi WANG

Bo ZHANG

Hao WANG

Jun LIANG

Yiming WU

Related Institution

Department of Radiation Oncology, Peking Union Medical College Hospital & Chinese Academy of Medical Sciences

National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Center of Respiratory Medicine, China-Japan Friendship Hospital

Department of Ultrasound, China-Japan Friendship Hospital

Japan Friendship Hospital (Institute of Clinical Medical Sciences), Peking Union Medical College, Chinese Academy of Medical Sciences,, China

Oncology Medical Center, Peking University International Hospital

AI问答

⁰